Aquestive appoints new CMO and adds independent director to Board

Aquestive Therapeutics, Inc.

Appointed Kenneth Truitt, M.D. as Chief Medical Officer effective Sept 6, 2022.
Dr. Truitt granted inducement option for 100,000 shares; vesting 25%/25%/50% over 3 years.
Appointed Timothy E. Morris to Board (Class I) effective Aug 5, 2022, filling newly created seat.
Mr. Morris receives 28,500 stock options vesting 1/3 annually; will serve on Audit Committee.
Board Chair Santo Costa steps down from Audit Committee; Board size increased to seven.

item 3.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy E. Morris

Director

AQST · Aquestive Therapeutics, Inc.

Effective: 2022-08-05
Filed: August 10, 2022, 7:59 PM ET

On August 10, 2022, the Company announced the appointment of Timothy E. Morris to the Company’s Board, effective August 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy E. Morris was appointed as Director at Aquestive Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 10, 2022, the Company announced the appointment of Timothy E. Morris to the Company’s Board, effective August 5, 2022.

View on SEC.gov

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-022271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.